Usefulness and reliability of cell free fetal DNA screening for main trisomies in case of atypical profile on first trimester maternal serum screening.

Abstract

BACKGROUND:

Patients with atypical values of HCG and/or PAPP-A are at higher risk of chromosomal abnormality and vascular complications of pregnancy. The performance of cfDNA in this particular population has not yet been evaluated.

OBJECTIVES:

The primary objective was to evaluate the usefulness and reliability of cfDNA in screening for trisomy 21, 18 and 13 for patients with HCG < 0.25 multiple of median (MoM), HCG > 5.0 MoM and/or PAPP-A < 0.25 MoM, PAPP-A > 2.5 MoM. The secondary objective was to evaluate the contribution of cfDNA assay for the prediction of pregnancy's vascular complications.

METHOD:

Between June 2016 and July 2017, we analysed a women cohort from all over France who had at least one first trimester serum biomarker outside of normal range, in a retrospective, observational and multicentre study. Patients were included if they had a single pregnancy, normal first trimester ultrasound examination, whatever the result of the combined first trimester screening test was. The cfDNA was analysed by massive parallel sequencing technique. The accuracy of cfDNA assay was evaluated by calculation of sensitivity and specificity, and multivariate regression analysis was used to search for predictive factors for pregnancy's vascular complications.

RESULTS:

Among the 498 patients who underwent a cfDNA assay in this context, twenty-one (4.2%) were excluded because of loss to follow-up. Out of 477, test failure occurred for four patients initially, reduced to two patients (0.4%) after redrawn. CfDNA was positive for Trisomy 21 (n = 19), Trisomy 18 (n = 6) and Trisomy 13 (n = 1) and negative in 449. The sensitivity of cfDNA assay for trisomy 21 screening was 100% (19/19) (IC 95% 82.4-100) and specificity 100% (458/458) (IC 95% 99.2-100). Among the 447 patients included for prediction of vascular complications, there were four cases of pregnancy induced hypertension and 10 cases of preeclampsia, for which no predictive factor was identified. Intra Uterine growth restriction under 5th percentile (n = 44, 9.8%) was significantly associated with a low fetal fraction (OR = 0.87, IC 95% 0.79-0.96, p = 0.006).

CONCLUSION:

cfDNA assay is an effective and reliable tool for women with atypical profile of first trimester serum biomarkers.

• Authors: Julie Carrara, Alexandre Vivanti, Jacques C Jani, Adèle Demain, Jean-Marc Costa, Alexandra Benachi
• Journal: Journal of translational medicine (J Transl Med) Vol. 17 Issue 1 Pg. 398 (11 28 2019) ISSN: 1479-5876 [Electronic] England
• PMID: 31779618 (Publication Type: Journal Article)

Chemical References

• Cell-Free Nucleic Acids

Topics

• Adult
• Cell-Free Nucleic Acids (blood, genetics)
• Cell-Free System
• Female
• Humans
• Logistic Models
• Mass Screening
• Middle Aged
• Pre-Eclampsia (blood, genetics)
• Pregnancy
• Pregnancy Complications (blood, diagnosis, genetics)
• Pregnancy Trimester, First (blood, genetics)
• Prenatal Diagnosis
• Reproducibility of Results
• Trisomy (genetics)
• Young Adult